These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38291942)

  • 1. Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore.
    Ochiai K; Yonezawa R; Fujii S
    ChemMedChem; 2024 Mar; 19(6):e202400040. PubMed ID: 38291942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-property and structure-activity relationships of phenylferrocene derivatives as androgen receptor antagonists.
    Ochiai K; Fujii S
    Bioorg Med Chem Lett; 2021 Aug; 46():128141. PubMed ID: 34048883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
    Koga H; Negishi M; Kinoshita M; Fujii S; Mori S; Ishigami-Yuasa M; Kawachi E; Kagechika H; Tanatani A
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of androgen receptor full antagonists bearing a p-carborane cage: promising ligands for anti-androgen withdrawal syndrome.
    Goto T; Ohta K; Fujii S; Ohta S; Endo Y
    J Med Chem; 2010 Jul; 53(13):4917-26. PubMed ID: 20521823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel androgen receptor antagonist, MEL-6, with stereoselective activity and optimization of its metabolic stability.
    Helsen C; Karypidou K; Thomas J; De Leger W; Nguyen T; Joniau S; Voet A; Dehaen W; Claessens F
    J Steroid Biochem Mol Biol; 2024 May; 239():106476. PubMed ID: 38311010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
    Zhou J; Liu B; Geng G; Wu JH
    Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
    Wakabayashi K; Imai K; Miyachi H; Hashimoto Y; Tanatani A
    Bioorg Med Chem; 2008 Jul; 16(14):6799-812. PubMed ID: 18571420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electronic effect-dependent intramolecular non-covalent interactions on the activity of 4,4-dimethylimidazolidin-2-one pharmacophore-based androgen receptor antagonists.
    Yaragani M; Yadlapalli P; Raghavan S; Giridhar T; Mandava VBR; Singh RV; Kottapalli RP; Chinnusamy S
    Chem Biol Drug Des; 2023 Mar; 101(3):614-625. PubMed ID: 36198102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
    Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
    Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.
    Singh P; Hallur G; Anchoori RK; Bakare O; Kageyama Y; Khan SR; Isaacs JT
    Prostate; 2008 Oct; 68(14):1570-81. PubMed ID: 18668523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
    Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
    Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
    Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.
    Helsen C; Marchand A; Chaltin P; Munck S; Voet A; Verstuyf A; Claessens F
    Mol Cancer Ther; 2012 Jun; 11(6):1257-68. PubMed ID: 22496481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.